HIGHLIGHTS
- who: Michael Winkelmann and collaborators from the University of, Italy have published the article: Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment, in the Journal: (JOURNAL)
- what: The authors investigated methods of TB assessment in the context of CD19 CART. The study has several limitations that should be considered when interpreting the results.
SUMMARY
Understanding the differences between TB assessment methods would enable standardization/harmonization in the context of clinical trials and high-quality real-world evidence. The authors therefore studied the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.